Affiliation:
1. Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca Macclesfield United Kingdom william.goundry@astrazeneca.com jeremy.parker@astrazeneca.com
Abstract
The interaction between Medicinal Chemistry and Process Chemistry is key to the success of drug projects. This chapter highlights differences between the two disciplines, discusses what needs to be considered prior to scale-up, and includes how to spot early warning signs. Collaboration opportunities at the interface of the disciplines are highlighted including: information sharing, sustainability, process safety and route design. The importance of process design to support scale-up is illustrated with case studies including: flow chemistry, high throughput experimentation, biocatalysis, photocatalysis and crystallisation. The interaction is put in the context of new emerging 21st century challenges and how medicinal chemists and process chemists can successfully tackle these together.
Publisher
The Royal Society of Chemistry
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献